WHO Prequalifies New Malaria Drug For Newborns and Infants
WHO has prequalified Coartem (artemether-lumefantrine) Baby, a new formulation designed for newborns and young infants weighing 2 to 5...
Double-Digit Revenue and EPS Growth Reported for Q1 2026
Sanofi opened 2026 with momentum: first-quarter sales reached €10.5 billion, up 13.6% at constant exchange rates, and business EPS...
Ipsen’s Surging Q1 2026 Sales Bolster Full-Year Guidance
Ipsen posted first‑quarter 2026 sales of €1.07 billion, up 17% as reported and 22.6% at constant exchange rates, and...
Exicure, Adbiotech Announce Co-Development Deal for Burixafor
Exicure has entered a co-development agreement with Korea-based ADBiotech to advance burixafor (GPC-100) in combination strategies across sickle cell...
New Briumvi MS Data Presented at AAN 2026 Annual Meeting
TG Therapeutics used the AAN 2026 stage to advance the positioning of BRIUMVI in relapsing multiple sclerosis, presenting new...
Capricor Announces Late-Breaking HOPE-3 Data at AAN 2026
Capricor Therapeutics presented Phase 3 HOPE-3 data for Deramiocel (CAP-1002) in Duchenne muscular dystrophy at the American Academy of...
US Approves Dupixent, First Biologic for Kids with CSU
FDA has approved Dupixent (dupilumab) for children aged two to 11 with chronic spontaneous urticaria (CSU) who remain symptomatic...
Elkedonia Appoints Pierre d’Epenoux to Strategic Committee
Elkedonia has appointed Pierre d’Epenoux as independent chairman as the Franco‑Belgian biotech advances a first‑in‑class program targeting ELK1 inhibition...
Humacyte Announces Breakthrough Symvess® App for Israel
Humacyte’s bid to globalize its bioengineered vascular graft moved a step forward as Israel’s Ministry of Health accepted the...
Prostact Phase 3 Data Selected for ASCO 2026 Spotlight
Telix Pharmaceuticals will deliver late-breaking Part 1 data from its global Phase 3 ProstACT study of TLX591-Tx, a PSMA-targeted...